MWNA
IOVA icon

Marshall Wace North America’s Iovance Biotherapeutics IOVA Stock Holding History

Marshall Wace North America’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-55,372
Closed -$1.75M – 1602
2021
Q1 		$1.75M Buy
+55,372
New +$2.3M 0.01% 862
2020
Q4 		– Sell
-44,724
Closed -$1.47M – 1431
2020
Q3 		$1.47M Sell
44,724
-289,448
-87% -$8.87M 0.01% 688
2020
Q2 		$9.17M Buy
334,172
+247,369
+285% +$8.13M 0.06% 278
2020
Q1 		$2.6M Buy
86,803
+77,955
+881% +$2.07M 0.02% 438
2019
Q4 		$245K Buy
+8,848
New +$201K ﹤0.01% 929
2019
Q3 		– Sell
-210,174
Closed -$5.15M – 1408
2019
Q2 		$5.15M Sell
210,174
-105,275
-33% -$1.59M 0.03% 356
2019
Q1 		$3M Buy
315,449
+247,321
+363% +$2.4M 0.02% 415
2018
Q4 		$603K Sell
68,128
-145,054
-68% -$1.4M 0.01% 735
2018
Q3 		$2.4M Sell
213,182
-324,486
-60% -$4.61M 0.02% 455
2018
Q2 		$6.88M Sell
537,668
-1,141,303
-68% -$16.7M 0.04% 433
2018
Q1 		$28.4M Buy
+1,678,971
New +$25.4M 0.14% 163
2017
Q3 		– Sell
-13,191
Closed -$92K – 1386
2017
Q2 		$92K Buy
+13,191
New +$83.9K ﹤0.01% 1255

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Marshall Wace North America's IOVA Position: Q2 2021 in Review

Marshall Wace North America sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 55,372 shares — an estimated $1.75M sold.

Marshall Wace North America first reported a position in IOVA in Q2 2017 and held it in 12 quarters. The position peaked at $28.4M in Q1 2018. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Marshall Wace North America reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 55,372 Iovance Biotherapeutics shares in Q2 2021, an estimated $1.75M.
  • Marshall Wace North America first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 12 quarters.
  • Marshall Wace North America's Iovance Biotherapeutics position peaked at $28.4M in Q1 2018.
  • 234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.